Key result
Low ATIII links to higher AKI in patients while ATIII therapy attenuates contrast-induced nephropathy in rats.
Why the study?
The relationship between antithrombin III level and contrast-induced nephropathy and the therapeutic effect of antithrombin III on CIN were not well understood.
Does antithrombin III protect against contrast-induced nephropathy?
Does antithrombin III protect against contrast-induced nephropathy?
Antithrombin III may represent a promising strategy for the prevention and treatment of contrast-induced acute kidney injury.
Answers are grounded in this paper and cite their sources.
May support antithrombin III supplementation for contrast-induced AKI prevention; hypothesis-generating and should not yet change practice.
We previously reported that insufficiency of antithrombin III (ATIII), the major anti-coagulation molecule in vivo, exacerbated renal ischemia-reperfusion injury in animal models and possibly humans. In the present study, we investigated the relationship between ATIII level and contrast induced nephropathy (CIN) in patients and examined therapeutic effect of ATIII on CIN in Sprague-Dawley rats. Patients with low ATIII activity presented a higher incidence of acute kidney injury (AKI) following coronary angiography. ATIII (500μg/kg) was intravenously injected before or after the induction of AKI in rats. Our data demonstrated ATIII significantly attenuated the elevation of serum creatinine, blood urea nitrogen, and renal histological injury. The beneficial effects of ATIII were accompanied by diminished renal inflammatory response, oxidative stress, cell apoptosis and improved renal blood flow in rats. In conclusion, ATIII appears to attenuate CIN through inhibiting inflammation, oxidative stress, apoptosis and improving renal blood flow. ATIII administration may represent a promising strategy for the prevention and treatment of contrast-induced AKI.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2017) studied Contrast-induced nephropathy (CIN) / Acute kidney injury (AKI). Antithrombin III (ATIII) was evaluated on Acute kidney injury (AKI) / contrast-induced nephropathy. Low antithrombin III activity was associated with higher AKI incidence in patients, while ATIII administration (500μg/kg) attenuated contrast-induced nephropathy in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: